Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients
Transfusion · 2025
DOI: 10.1111/trf.18131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Transfusion, 2025. Verfasst von Philip J Norris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Isoantibodies, Glutathione, HLA Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Biomedical Advanced Research and Development Authority, US Dept of Health and Human Services, ClinicalTrials.gov.
Abstract (Originalsprache)
Background
Although alloimmunization risk of pathogen‐reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs). Study Design and Methods In a Phase III, randomized, controlled trial (Red Cell Pathogen Inactivation), cardiac or thoracic‐aorta surgery patients were randomized to transfusion with amustaline/glutathione PR versus conventional RBCs. Pre‐transfusion and Day 28 samples were evaluated for Human leukocyte antigen (HLA) Class I and Class II antibodies at low, medium, and high cutoff values.
Results
The HLA alloimmunization analysis included 114 participants (53% female) in the PR and 113 (51% female) in the conventional RBC arms. In a modified intention‐to‐treat analysis, 13.7% ( N = 29) and 7.2% ( N = 15) developed new high‐level HLA Class I or Class II antibodies, respectively; however, there was no signal that PR‐RBCs affected the rate of HLA Class I (odds ratio (OR) 1.3 [95% confidence interval (CI) 0.62–2.9]) or Class II antibody formation (OR 0.99 [95% CI 0.35–2.8]). Female transfusion recipients had higher risk of developing new high‐level HLA Class I antibodies (OR 12.0 [95% CI 3.5–40.9]) and Class II antibodies (OR 5.0 [95% CI 1.4–17]). The mean number of RBC (5.5 vs. 3.6 units, p = 0.018) and platelet (1.8 vs. 1.1 units, p = 0.043) transfusions was higher in subjects with new high‐level HLA Class II antibodies.
Discussion
Receipt of amustaline/glutathione PR‐RBC units did not affect HLA alloimmunization risk. Female sex and number of RBC and platelet transfusions were risk factors for the development of new high‐level HLA Class I and Class II antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitalant Research Institute, San Francisco, California, USA.
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
- Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
- Cerus Corporation, Concord, California, USA.
ORCID-Profile: Philip J Norris, Clara Di Germanio, Laurence Corash, Richard J Benjamin
Förderung
- Biomedical Advanced Research and Development Authority
- US Dept of Health and Human Services
- ClinicalTrials.gov
- Cerus Corporation
Zitieren
APA
Norris, P. J., Stone, M., Di Germanio, C., Balasko, B., Kaidarova, Z., Friend, H., Varrone, J., Corash, L., Mufti, N., & Benjamin, R. J. (2025). Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients. Transfusion. https://doi.org/10.1111/trf.18131
Vancouver
Norris PJ, Stone M, Di Germanio C, Balasko B, Kaidarova Z, Friend H, et al. Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients. Transfusion. 2025. doi:10.1111/trf.18131
BibTeX
@article{Norris2025,
author = {Norris, Philip J and Stone, Mars and Di Germanio, Clara and Balasko, Brendan and Kaidarova, Zhanna and Friend, Henry and Varrone, Jeanne and Corash, Laurence and Mufti, Nina and Benjamin, Richard J},
title = {Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18131}
}
EUVIMED